Skip to content
Americans are frustrated with the health care system for two reasons. First, it costs too much. But—second—it provides too little. While most of the […]
Nearly half of Americans say insurers’ rules on access delayed, denied, or altered care Read More »
We could be in for another big year of biotech M&A. A busy 2025, in both licensing and M&A in biopharma, saw over 4,000
BIG Summit: Experts see signs of M&A momentum in 2026 Read More »
China is becoming an increasingly influential player in the global biotech market. More than a third of U.S. licensing deals this year have involved
BIG Summit: Seeking opportunities while navigating risks of global trade Read More »
The Medicare drug price “negotiation” process has entered its third year, with some evolution but continued complexity for patients and patient organizations. This year,
BIO Patient Advocacy Coffee Chat: Act now to be heard on CMS drug pricing Read More »
The inaugural Biotechnology Innovation Organization (BIO) Investment and Growth (BIG) Summit kicks off on March 2, 2025, and will convene industry leaders in sunny
Meet us in Miami for the BIO Investment and Growth Summit Read More »
The Valley of Death is a healthcare crisis, but the nonprofit, Music Beats Cancer, has an innovative way to help solve it, and it
Music Beats Cancer aims to bring everyone to the stage Read More »
Patient advocacy organizations that leverage venture philanthropy—an approach to philanthropic giving that applies venture capital principles to achieve philanthropic goals—can provide vital funding sources
The BIG Summit meets at the intersection of patient advocacy and venture investment Read More »
Most Favored Nation (MFN) type drug pricing proposals that were proposed by the Centers for Medicare & Medicaid Innovation (CMMI) in December 2025 would
BIO Coffee Chat: MFN proposals would harm innovation and access Read More »
Pharmacy benefit managers (PBMs) were identified as a major driver behind higher prescription drug costs in a congressional hearing that featured testimony from BIO
BIO CEO testifies in hearing highlighting PBMs’ impact on drug prices Read More »
National Institutes of Health (NIH) Director Jay Bhattacharya acknowledged there are no studies indicating a link between any vaccine and autism as Senators pushed
NIH Director says no studies link vaccines and autism in hearing on modernization Read More »
